Referencias bibliográficas

  1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis. Journal of the American Academy of Dermatology. febrero de 2014;70(2):338-51.

  2. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Annals of Nutrition and Metabolism. 2015;66(1):8-16.

  3. Leung DYM, Boguniewicz M, Howell MD, Nomura I, Hamid QA. New insights into atopic dermatitis. J Clin Invest. 2004;113(5):651-657.

  4. Holm E, Esmann S, Jemec G. The handicap caused by atopic dermatitis - sick leave and job avoidance. Journal of the European Academy of Dermatology and Venereology. marzo de 2006;20(3):255-9.

  5. Gittler JK et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.

  6. Mayo Clinic. Dermatitis. [Internet]. Disponible en: https://www.mayoclinic.org/diseases-conditions/dermatitis-eczema/symptoms-causes/syc-20352380. Revisado en Febrero 2025

  7. Torrelo A. Atopic dermatitis in different skin types. What is to know? JEADV. 2014;28(Suppl. 3):2-4.

  8. National Institute of Arthritis and Musculoskeletal and Skin Diseases. What is Atopic Dermatitis? [Internet]. Disponible en: https://www.niams.nih.gov/health-topics/atopic-dermatitis. Revisado en Febrero 2025

  9. Zuberbier T, Orlow SJ, Paller AS, Taïeb A, Allen R, Hernanz-Hermosa JM, et al. Patient perspectives on the management of atopic dermatitis. Journal of Allergy and Clinical Immunology. julio de 2006;118(1):226-32.

  10. Yosipovitch G, Papoiu ADP. What causes itch in atopic dermatitis? Current Allergy and Asthma Reports. julio de 2008;8(4):306-11.

  11. Stander S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Experimental Dermatology. febrero de 2002;11(1):12-24.

  12. Bieber T. Atopic Dermatitis. Annals of Dermatology. 2010;22(2):125.

  13. Myers JE. The wheel of wellness: Counseling for wellness. Journal of Counseling and Development. 2000.

  14. Rosenkranz MA, Davidson RJ, MacCoon DG, Sheridan JF, Kalin NH, Lutz A. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain, Behavior, and Immunity. enero de 2013;27:174-84.

  15. Neff KD, Kirkpatrick KL, Rude SS. Self-compassion and adaptive psychological functioning. Journal of Research in Personality. febrero de 2007;41(1):139-54.

  16. Berkman LF, Glass T, Brissette I, Seeman TE. From social integration to health: Durkheim in the new millennium. Social Science. 2000;15.

  17. Mayo Clinic. Support groups: Make connections, get help. [Internet]. Disponible en: https://www.mayoclinic.org/healthy-lifestyle/stress-management/in-depth/support-groups/art-20044655. Revisado en Febrero 2025.

  18. Lifschitz C. The Impact of Atopic Dermatitis on Quality of Life. Annals of Nutrition and Metabolism. 2015;66(1):34-40.

  19. Suárez-Fariñas M, et al. Non-lesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011;127(4):954-964.

  20. Rerknimitr P, Otsuka A, Nakashima C, et al. The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. Inflamm Regener. 2017;37:14. https://doi.org/10.1186/s41232-017-0044-7.

  21. Hendricks AJ, et al. Sweat mechanisms and dysfunctions in atopic dermatitis. Journal of Dermatological Science. 2018;89:105-111.

  22. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5:691-706.

  23. Medicamentos inhalables contra el asma consejos para tener en cuenta (Inhaled Asthma Medications). [Internet] . Disponible en: https://www.aaaai.org/tools-for-the-public/biblioteca-de-condiciones/biblioteca-de-asma/medicamentos-inhalables-contra-el-asma-consejos-pa?utm_source=chatgpt.com. Revisado en Febrero 2025

  24. U.S Department of Health and Human Services-National Institutes of Health; National Heart, Lung and Blood Institute (2007). NIH Guidelines for the Diagnosis and Management of Asthma, National Asthma Education and Prevention Program Expert Panel Report 3, p. 13-54.

  25. Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinical management of asthma in 1999: the AIRE study. Eur Respir J. 2000;16:802-807.

  26. Fletcher M, Hiles D. Continuing discrepancy between patient perception of asthma control and real-world symptoms: a quantitative online survey of 1,083 adults with asthma from the UK. Prim Care Resp J. 2013;22(4):431-438.

  27. Murphy KR, et al. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc. 2012;33(1):54-64.

  28. Andrews KL, et al. Stigma: Still an Important Issue for Adults With Asthma. Journal of Asthma and Allergy Educators. 2013;4(4).

  29. Reddel HK, et al. Risks associated with managing asthma without a preventer: BMJ Open. 2017;7:e016688. [Internet]. Disponible en: https://bmjopen.bmj.com/content/7/9/e016688.full . Revisado en Febrero 2025

  30. Bülow AV, et al. The Prevalence of Severe Asthma and Low Asthma Control Among Danish Adults. J Allergy Clin Immunol. 2014;2(6):759-767.

  31. Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2018. [Internet]. Disponible en: http://ginasthma.org/download/832/. Revisado en Febrero 2025

  32. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.

  33. Heffler, E., Blasi, F., Latorre, M., Menzella, F., Paggiaro, P., Pelaia, G., Senna, G., Canonica, G. W., & SANI Network (2019). The Severe Asthma Network in Italy: Findings and Perspectives. The journal of allergy and clinical immunology. In practice, 7(5), 1462–1468. https://doi.org/10.1016/j.jaip.2018.10. Revisado en Febrero 2025

  34. Juniper EF, GH Guyatt, PJ Ferrie, et al. Measuring Quality of Life in Asthma. Am Rev Respir Dis. 1993;147:832-8.

  35. Asthma and Allergy Foundation of America. My Life with Asthma Report. [Internet]. Disponible en: http://www.aafa.org/my-life-with-asthma-report/. Revisado en Febrero 2025

  36. Rand C, et al. Mediators of asthma outcomes. J Allergy Clin Immunol. 2012:129(3);136-141.

  37. Steinke, J. W., & Wilson, J. M. (2016). Aspirin-exacerbated respiratory disease: pathophysiological insights and clinical advances. Journal of asthma and allergy, 9, 37–43. [Internet]. Disponible en: https://doi.org/10.2147/JAA.S88739. Revisado en Febrero 2025

  38. The European Academy of Allergy and Clinical Immunology (EAACI). Advocacy Manifesto: Tackling the Allergy Crisis in Europe - Concerted Policy Action Needed. [Internet]. Disponible en: eaaci_advocacy_manifesto.pdf. Revisado en Febrero 2025

  39. Behmanesh F, et al. Evaluation of anxiety and depression in mothers of children with asthma. Electron Physician. 2017:9(12);6058-6062.

  40. European Respiratory Society. European Lung White Book, Chapter 2: The economic burden of lung disease. [Internet]. Disponible en: The European Lung White Book - ERS - European Respiratory Society  Revisado en Febrero 2025

  41. Daugherty J, et al. The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. J Asthma. 2017 Sep;19:1-8.

  42. Nunes C, Pereira AM, Morais-Ameida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1

  43. Chipps et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2012 Aug;130(2):332-42.

  44. Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 2016;15(1):35-50

  45. Woodruff PG, et al. T-helper Type 2–driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009;180(5):388–395

  46. Peters MC, Mekonnen ZK, Yuan S, et al. Measure of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol. 2014;133(2):388-394

  47. Fahy et al. Type 2 inflammation in asthma--present in most, absent in many. Nat Rev Immunol. 2015 Jan;15(1):57-65.

  48. Dunican EM, Fahy JV. The Role of type 2 inflammation in the pathogenesis of asthma exacerbations. Ann Am Thorac Soc.2015;12 Suppl 2:S144–S149

  49. Muraro A, Lemanske RF, Hellings PW, et al. Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol. 2016;137(5):1347-58

  50. Ray A, Oriss TB, Wenzel SE. Emerging molecular phenotypes of asthma. Am J Physiol Lung Cell Mol Physiol. 2015;308(2):L130-40

  51. Matsusaka M, K Fukunaga, H Kabata, et al. Subphenotypes of type 2 severe asthma in adults. J Allergy Clin Immunol Pract 2018;6(1):274-276.e2

  52. Robinson D, Humbert M, Buhl R, et al. Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy. 2017. 47(2): 161-175.

  53. Partridge, M. R. Delivering optimal care to the person with asthma: what are the key components and what do we mean by patient education? Eur Respir J. 1995: 8: 298-305.

  54. Forum of International Respiratory Societies. The Global Impact of Respiratory Disease – Second Edition. Sheffield, European Respiratory Society, 2017.

  55. Global Initiative for Asthma. Difficult-to-treat & severe asthma in adolescent and adult patients, 2019 (Iniciativa Global para el Asma. Asma grave y difícil de tratar en pacientes adolescentes y adultos, 2019). [Internet]. Disponible en:  https://ginasthma.org/wp-content/uploads/2019/04/GINA-Severe-asthma-Pocket-Guide-v2.0-wms-1.pdf. Revisado en Febrero 2025

  56. Chung, K. F., et al (2013). International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. European Respiratory Journal, 43(2), 343-373. ). [Internet]. Disponible en: https://doi.org/10.1183/09031936.00202013. Revisado en Febrero 2025

  57. The Global Asthma Report 2018. Auckland, New Zealand: Global Asthma Network, 2018

  58. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials [published correction appears in Lancet. 2019 Nov 2;394(10209):1618]

  59. Guilemany, J. M. (2006). ¿Cómo diagnosticar a un paciente con rinosinusitis crónica/poliposis nasal? Jano: Medicina y humanidades, 1665, 29-34. [Internet]. Disponible en: https://dialnet.unirioja.es/servlet/articulo?codigo=2376595. Revisado en Febrero 2025

  60. Bachert C, Gevaert E. Advances in rhinitis and rhinosinusitis in 2015. J Allergy Clin Immunol. 2016;138(5):1277-1283

  61. Gandhi NA, Bennett BL, Graham NM, Pirozzi G, Stahl N, Yancopoulos GD. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35-50

  62. Khan A, Vandeplas G, Huynh TMT, et al. The Global Allergy and Asthma European Network (GALEN) rhinosinusitis cohort: a large European cross-sectional study of chronic rhinosinusitis patients with and without nasal polyps. Rhinology. 2019;57(1):32-42

  63. Chaaban MR, Walsh EM, Woodworth BA. Epidemiology and differential diagnosis of nasal polyps. Am J Rhinol Allergy. 2013;27(6):473-478

  64. Van Zele T, Claeys S, Gevaert P, et al. Differentiation of chronic sinus diseases by measurement of inflammatory mediators. Allergy. 2006;61(11):1280-1289

  65. Van Zele T, Holtappels G, Gevaert P, Bachert C. Differences in initial immunoprofiles between recurrent and nonrecurrent chronic rhinosinusitis with nasal polyps. Am J Rhinol Allergy. 2014;28(3):192-198

  66. Yasir M, Goyal A, Bansal P, et al. Corticosteroid Adverse Effects. [Updated 2020 Apr 13]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. [Internet]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK531462/. Revisado en Febrero 2025

  67. DeConde AS, Mace JC, Levy JM, Rudmik L, Alt JA, Smith TL. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127(3):550-555

  68. Bassiouni A, Wormald PJ. Role of frontal sinus surgery in nasal polyp recurrence. Laryngoscope. 2013;123(1):36-41

  69. Wynn R, Har-El G. Recurrence rates after endoscopic sinus surgery for massive sinus polyposis. Laryngoscope. 2004;114(5):811-813

  70. Bebés y niños con dermatitis atópica. (2016, noviembre 4). MedPlus; MedPlus Medicina Prepagada. [Internet]. Disponible en:  https://www.medplus.com.co/bebes-y-ninos-con-dematitis-atopica/. Revisado en Febrero 2025

  71. World Health Organization. Asma. Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/asthma. Revisado en Febrero 2025. Revisado en Febrero 2025

  72. Medline. Asma. (2002). Immune System. [Internet]. Disponible en:  https://medlineplus.gov/spanish/asthma.html. Revisado en Diciembre 2023

  73. National Institutes of Health; National Heart, Lung and Blood Institute. (2018). Clinical Practice Guidelines. P, 1–11.

  74. Sociedad Catalana de Alergia e Inmunología Clínica, Sociedad Catalana de Neumología, Sociedad Catalana de Otorrinolaringología y Patología Cervicofacial, Sociedad Catalana de Farmacia Clínica, Sociedad Catalana de Dermatología y Venereología, Sociedad Catalana de Digestología, asociación A Tot Pulmó. Documento de consenso para la mejora del abordaje de la Inflamación de Tipo 2 y sus patologías asociadas en Cataluña. [Internet]. Disponible en: maquetacion-sanofi-castellano.pdf. Revisado en Febrero 2025

  75. You may not be “sick,” but talk with your doctor about better asthma control. (s/f). Home. Recuperado el 6 de diciembre de 2023, de https://www.thenextbreath.com/blog/you-may-not-be-sick-but-talk-with-your-doctor-about-better-asthma-control.

  76. Asthma Control Questionnaire. (2023, abril 8). Asthma Australia. [Internet]. Disponible en:https://asthma.org.au/acq/. Revisado en Febrero 2025

  77. Bienvenido a la FID. (2020, noviembre 6). Federación Internacional de Diabetes. [Internet]. Disponible en: https://idf.org/es/. Revisado en Febrero 2025

  78. American Heart Association. (2024). [Internet]. Disponible en: https://www.heart.org/en. Revisado en Febrero 2024

  79. American Diabetes Association (ADA). (2024). Diabetes Research, Education, Advocacy. [Internet]. Disponible en: https://diabetes.org/. Revisado en Febrero 2025

  80. National Institutes of Health (NIH). (2024). National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). [Internet]. Disponible en: https://www.niddk.nih.gov/. Revisado en Febrero 2025

  81. U.S. Food and Drug Administration (FDA). [Internet]. Disponible en: https://www.fda.gov/food/nutrition-education-resources-materials/el-sodio-en-su-dieta. Revisado en Febrero 2025

  82. Centers for Disease Control and Prevention (CDC). (2024). Centers for Disease Control and Prevention. [Internet]. Disponible en: https://www.cdc.gov/. Revisado en Febrero 2025

  83. Mayo Clinic. (2024). Presión arterial alta (hipertensión). [Internet]. Disponible en: https://www.mayoclinic.org/es/diseases-conditions/high-blood-pressure/symptoms-causes/syc-20373410. Revisado en Febrero 2025

  84. National Heart, Lung, and Blood Institute (NHLBI). (2023, enero). Advancing Heart, Lung, Blood, and Sleep Research & Innovation. [Internet]. Disponible en: https://www.nhlbi.nih.gov/. Revisado en Febrero 2025

  85. Organización Mundial de la Salud (OMS). (2024). [Internet]. Disponible en: https://www.who.int/about. Revisado en Febrero 2025

  86. StatPearls Publishing. (2022). StatPearls - NCBI Bookshelf. [Internet]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK430685/  Revisado en Febrero 2025

  87. Gastroenterology & Hepatology. (2017). The Role of Lipids in Nonalcoholic Fatty Liver Disease. https://pmc.ncbi.nlm.nih.gov/articles/PMC5483621/.